NEW YORK (GenomeWeb) – Cynvenio Biosysterms and Color announced an agreement today to offer a combined version of their respective liquid biopsy and hereditary cancer tests.

Using the new offering, clinicians can test breast cancer patients for alterations in the 30 genes on Color's hereditary cancer panel, as well as for somatic cancer mutations in the 27 genes that Cynvenio's ClearID breast cancer test covers.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.